Background/Aims: How to aid recovery from severe skin injuries, such as burns, chronic or radiation ulcers, and trauma, is a critical clinical problem. Current treatment methods remain limited, and the discovery of ideal wound-healing therapeutics has been a focus of research. Functional recombinant proteins such as basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF) have been developed for skin repair, however, some disadvantages in their use remain. This study reports the discovery of a novel small peptide targeting fibroblast growth factor receptor 2 IIIc (FGFR2IIIc) as a potential candidate for skin wound healing. Methods: A phage-displayed peptide library was used for biopanning FGFR2IIIc-targeting small peptides. The selected small peptides binding to FGFR2IIIc were qualitatively evaluated by an enzymelinked immunosorbent assay. Their biological function was detected by a cell proliferation assay. Among them, an optimized small peptide named H1 was selected for further study. The affinity of the H1 peptide and FGFR2IIIc was determined by an isothermal titration calorimetry device. The ability of theH1 peptide to promote skin wound repair was investigated using an endothelial cell tube formation assay and wound healing scratch assay in vitro. Subsequently, the H1 peptide was assessed using a rat skin full-thickness wound model and chorioallantoic membrane (CAM) assays in vivo. To explore its molecular mechanisms, RNA-Seq, quantitative real-time PCR, and western blot assays were performed. Computer molecular simulations were also conducted to analyze the binding model. Results: We identified a novel FGFR2IIIc-targeting small peptide, called H1, with 7 amino acid residues using phage display. H1 had high binding affinity with FGFR2IIIc. The H1 peptide promoted the proliferation and motility of fibroblasts and vascular endothelial cells in vitro. In addition, the H1 peptide enhanced The H1 peptide has a high affinity for FGFR2IIIc and shows potential as a wound healing agent. As a substitute for bFGF, it could be developed into a novel therapeutic candidate for skin wound repair in the future.
Introduction
The skin, including the epidermis (surface layer) and dermis (deeper layer), is the largest barrier between the human body and the external environment. When this barrier is broken, an orchestrated cascade of biochemical events is set in motion to repair the damage [1, 2] . The classic model of wound healing involves three sequential phases: inflammation, proliferation, and remodeling [3, 4] . This process requires the collaboration of a variety of tissues and cell types, including inflammatory cells, fibroblasts, keratinocytes, endothelial cells, and macrophages [5, 6] . These cells are tightly regulated by cytokines, growth factors, and extracellular matrix molecules [7] [8] [9] . Although recombinant growth factors and cytokines have been clinically applied in treating skin damage, disadvantages in their use include their easy degradation and instability in vitro [10, 11] , and the highest clinical cure rate remains at 50-60% [12] . Therefore, it is necessary to identify novel biological products with low cost and easy storage.
The fibroblast growth factor receptor (FGFR)family plays an important role in organ development and consists of 4 members (FGFR1, FGFR2, FGFR3 and FGFR4). In addition, alternate mRNA splicing generates the "b" and "c"variants of FGFR 1, 2, and 3 [13, 14] . FGFR2 [15] is a receptor for FGF which is important in embryonic development and tissue repair, particularly of bone and blood vessels [16] [17] [18] . FGFR2-associated signaling pathways are activated by receptor binding with its ligands [19] . Its intracelluar tyrosine kinase domains are dimerized and phosphorylated to initiate a cascade of intracellular signals that mediate cell division, growth, and differentiation [18, [20] [21] [22] . Basic fibroblast growth factor (bFGF), also named FGF2, plays an important role in wound healing [23, 24] . Our institute successfully developed the recombinant bFGF for the treatment of burns, scalds, and chronic ulcers 20 years ago. However, recombinant bFGF has a large molecular weight and a high production cost. In clinical applications, there is also the low accumulation of bFGF at on therapeutic sites, an undesired effect. In addition to bFGF, other recombinant growth factors and cytokines show similar effects.
Compared with recombinant proteins, small peptides have many characteristics such as small molecular weight and low production cost that enable them to overcome the current high cost of producing recombinant proteins. In the present study, using phage display, we obtained an FGFR2IIIc-targeting small peptide, H1, which had a significant therapeutic effect on the healing of skin wounds.
Materials and Methods

Cell lines and cultures
Human umbilical vein endothelial cells (HUVECs), BALB/c 3T3 cells, and FGFR2IIIc-overexpressing HEK293 cells were maintained in our laboratory. All cells were cultured in high-glucose Dulbecco ， s modified Eagle ， s medium ( DMEM) supplemented with 10% fetal bovine serum (FBS) at 37°C in a humidified incubator under 5% CO 2 . The culture medium was changed every 2-3 days.
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Cellular Physiology and Biochemistry sterile water. These samples were thoroughly degassed and then centrifuged to remove precipitates. The binding of both was measured by ITC using a MicroCal Omega ITC200 system (MicroCal, Northampton, MA) at 25°C using 0.1 mM H1 peptide in the sample cell and 0.001 mM FGFR protein in the injecting syringe. Throughout the experiment, 19 drops were injected into the sample cell, and each drop had a volume of 2 μL. The interval between each drop was 5 min. ITC data were analyzed with a single-site binding model using Origin 7.0 software (OriginLab Corp., Northampton, MA).
Fibroblast wound scratch assay BALB/c 3T3 cells (3.0 × 10 4 ) were seeded in a 6-well plate and incubated at 37°C in 5% CO 2 for 24 h to create confluent monolayers. Next, after 12 h of serum starvation (DMEM supplemented with 0.5% FBS), the cell monolayer was subjected to a mechanical scratch wound using a sterile pipette tip and washed twice with phosphate-buffered saline to remove floating cells. Then, the cells were incubated with the H1 peptide (20 μM) for 24 h. During the experiment, bFGF (30 ng/mL) was used as a positive control. After 24 h, the images were obtained using a microscope, and cell migration activity was quantified using the ImageJ software (National Institutes of Health, Bethesda, MD). The migration ratio was calculated as follows: (the width of the original scratch -the width of the actual scratch) / (the width of the original scratch) × 100. Experiments were conducted independently in triplicate.
Endothelial cell tube formation assay
Matrigel (Cat #356230, BD Biosciences, Bedford, MA) was dissolved at 4°C overnight. In advance, 96-well plates and pipette tips were precooled. Matrigel matrix (80 μL) was added to each well of the precooled 96-well plate and incubated for 30 min at 37°C. HUVECs (2.0 × 10 4 ) were seeded into the 96-well plate and cultured in serum-free medium, including the H1 peptide (20 μM). During the experiment, bFGF (30 ng/mL) was used as a positive control. After 12 h of incubation at 37°C, HUVEC tube formation was photographed under a light microscope and quantified using ImageJ software. Experiments were conducted independently in triplicate.
Chorioallantoic membrane assay
Angiogenesis was assayed using a chorioallantoic membrane assay. Seventy fertilized chicken eggs were incubated at 37°C in a 60-70% humidified atmosphere. On day 6, the H1 peptide, dissolved in normal saline at different concentrations (1, 10, 100 and 1000 μM, 100 μL), was added to the center of the chorioallantoic membrane. bFGF (100 ng/mL) and normal saline were used as positive and negative controls, respectively. There were 10 eggs in each group. After 2 days of incubation, chorioallantoic membranes were photographed under a stereomicroscope. Angiogenesis was quantified by counting the number of blood vessel branches using Image-Pro Plus v 6.0 software (Media Cybernetics, Rockville, MD).
Rat skin full-thickness wound model
Male Sprague-Dawley rats, weighting 200-220 g, were injected intraperitoneally with 40 mg/kg pentobarbital sodium dissolved in normal saline. Dorsal hair was removed using an electric clipper. Six-6 mm full-thickness excisional wounds were created on the back of each rat using 9-mm diameter operating scissors and sterilized with 75% alcohol. After wounding, the rats were housed separately until the end of the experiment. Wounded rats were divided randomly into 3 groups (3 rats per group). The rats were treated with the H1 peptide (10 μg/mL, 20 μL) applied topically to the wound site twice daily. bFGF (100 μg/mL) and normal saline were used as positive and negative controls, respectively. The wound was photographed with a digital camera once every 2 days. One week later, all of the rats were euthanized, and the injured area was analyzed further.
Histology and immunohistochemistry
Skin tissues were obtained from sacrificed rats and processed into paraffin sections (5-mm thick) for further investigation. Tissue sections were stained with hematoxylin and eosin (HE) for morphological assessment. Immunohistochemical staining for proliferating cell nuclear antigen (PCNA), CD31, CK19, and vascular endothelial growth factor (VEGF) was performed with specific antibodies for each protein (Santa Cruz Biotech, Santa Cruz, CA). First, sections that were dewaxed and hydrated were blocked with 3% H 2 O 2 for 10 min, followed by blocking with 1% BSA for 30 min. Then, the sections were incubated with primary antibodies (at a dilution of 1:100) overnight at 4°C. Next, sections were incubated with biotinylated secondary antibodies (at a dilution of 1:200) at room temperature for 30 min, followed by incubation with HRP-streptavidin (at a dilution of 1:400) for 30 min. Finally, the sections were stained with DAB for 3-5 min, followed by hematoxylin counterstaining, dehydration, and coverslipping. All samples were observed through a high-power light microscope (Nikon, Tokyo, Japan).
RNA-Seq
The sequencing libraries were constructed following the TruSeqTM RNA Sample Preparation Guide (Illumina, San Diego, CA). When library construction ended, the library preparations were sequenced on an Illumina HiSeq 2500 platform and 125-bp paired-end reads were generated. Subsequently, sequence read mapping, assembly, and annotation were conducted. During the process, raw data (raw reads) infastq format were first processed through in-house Perl scripts. In this step, clean data (clean reads) were obtained by removing reads containing an adapter, reads containing poly-N, and low-quality reads from the raw data. Simultaneously, Q20, Q30, GC-content, and sequence duplication level of the clean data were calculated. All of the downstream analyses were based on high-quality clean data. High-quality reads were mapped to a human mRNA reference sequence (hg19 2015-03-17). mRNA abundance was normalized using both reads per kilobase per million reads and edgeR [25] package methods. Genes with >10 mapped reads were considered to be quantified genes. Meanwhile, the screening threshold in the differential expression analysis of transcripts was set to |log2 (FoldChange)| > 1 and P < 0.05. That is, genes with a P-value < 0.05 were designated as differentially expressed. In the relevant literature, more detailed processes are described [26] .
Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of differentially expressed transcripts
GO is divided into three aspects: molecular functions, biological processes, and cell composition. We used topGO (version 2. 18 .0) to analyze differentially expressed genes (DEGs) for GO enrichment, and Fisher ， s, exact test was used for statistical analysis. In vivo, different genes coordinate their biological functions with one another. By pathway enrichment, the major biochemical metabolic pathways and signal transduction pathways involved in the differential expression of genes can be determined. We screened the DEGs using KEGG pathway enrichment analysis. The analysis software was KOBAS (version 3.0) [27] , and the statistical test method was the hypergeometric test. P < 0.05 was defined as statistically significant.
RNA extraction and quantitative real-time PCR (qPCR) analysis
Total RNA was extracted from HUVECs using RNAiso plus (Cat #9108/9109, TaKaRa, Dalian, China) following the manufacturer ， s instructions. Total RNA (1 μg) was reverse-transcribed into cDNA using a PrimeScript TM RT Reagent Kit with gDNA Eraser (Cat #RR047A, TaKaRa). Real-time PCR was performed with SYBR ® Premix Ex Taq TM (Cat #RR820A, TaKaRa) in a CFX96 Real-Time PCR Detection System (Bio-Rad, Hercules, CA) with the following conditions: 95°C for 30 s, and 39 cycles of 95°C for 5 s, 55°C for 30 s, and 72°C for 30 s. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. Each plate had 3 repeated samples, and the reactions were performed 3 times independently. Gene expression was evaluated by the 2 −∆∆Ct method [28] . The primer sequences are listed in Supplementary Table 1 (For all supplemental material see www.karger.com/10.1159/000493287/).
Western blot analysis
The cells were lysed using RIPA lysate (Cat #P00138, Beyotime, Shanghai, China) containing proteinase inhibitors. Protein samples of the same concentration were separated by 12% sodium dodecyl sulfatepolyacrylamide gel electrophoresis. The separated protein samples were transferred to a polyvinylidene fluoride membrane using electrophoresis. Subsequently, the membrane was blocked with 5% (w/v) BSA for 1 h at room temperature and incubated with primary antibodies at 4°C overnight. The primary antibodies used in the experiments were as follows: anti-Akt antibody, anti-Phospho-Akt (Ser473) (D9E) XP® rabbit monoclonal, anti-p44/42 MAPK (Erk1/2),anti-phospho-p44/42 MAPK (Erk1/2) (Thr202/ Tyr204), and anti-β-actin (Cell Signaling Technology, Beverly, MA). The blots were washed 5 times with TBST and incubated with a secondary antibody (Cell Signaling Technology) for 1 h at room temperature. The blots were washed again 5 times with TBST and then developed using enhanced chemiluminescence (Cat #34096, Thermo Fisher Scientific, Rockford, IL).
ELISA
HUVECs were cultured in 24-well culture plates overnight. Then, the cells were pretreated with the H1 peptide at a gradient concentration and incubated in a humidified incubator at 37°C for 24 h. After incubation, VEGF in the medium was detected using a VEGF Human ELISA Kit (Cat #KHG0112, Thermo Fisher Scientific) according to the manufacturer ， instructions.
Molecular docking calculations and molecular dynamics simulations
Molecular docking is a computer simulation approach that attempts to predict the binding mode and affinity of a ligand to the active site of a protein [29] [30] [31] . Molecular docking of the H1 peptide on the extracellular segment of FGFR2IIIc protein was evaluated with LeDock software (http://www.lephar.com/). LeDock is based on a combination of simulated annealing and genetic algorithms. The crystal structure of the FGFR2IIIc extracellular domain was derived from the Protein Data Bank (PDB ID:1EV2). All calculations were performed on an Ubuntu Linux 16.04 platform. During the docking process, we removed the water molecules and hydrogen atoms of the crystal structure of the FGFR2IIIc extracellular domain while retaining the F chain as the template molecular docking chain. Later, we re-added the hydrogen atoms to ensure the protonation of the amino acid residues and corrected the irrational chemical bonds. Docking scores were calculated by the binding free energies. The optimal conformation was obtained as our further analysis object. Next, we conducted molecular dynamics simulations of 50 ns to verify the stability of the H1-FGFR2IIIc complex in ionic solvents. We used the Gromacs5.1.4 program to perform full atom molecular dynamics simulation of the complex under the CHARMM27 force field. The complex entered the 12-body periodic simulation box at 1.2 nm away from its boundary. First, we minimized the energy of the complex in a hypothetical vacuum. The judgment basis of energy convergence was set at 100.0 KJ mol -1 nm -1
, and convergence was achieved after 4376 steps. Next, we used the SPC/E water model to fill the simulation box with solvents. To maintain the system ， s electrostatic charge balance, we added 118 Na ions and 122 Cl ions, and eventually the ionic concentration of the solution reached 150 mM. Then, we conducted a positionconstrained pre-equilibrium simulation. In this process, we used the LINCE algorithm to constrain the chemical bonds of the complex system. The accuracy of LINCE was set to 1. The order of LINCS was set to 4. The truncation value of the electrostatic action was set to 1.0 nm. Simultaneously, we used the particle mesh Ewald electrostatic method to calculate the electrostatic interaction. In the process of molecular dynamics simulation, we first performed a pre-equilibrium simulation of 100 ps under the NVT ensemble and then performed a pre-equilibrium simulation of 100 ps under NPT. Finally, the finished product simulation of 50 ns was performed under NPT.
Statistical analysis
All data are shown as the mean ± standard deviation (SD). Differences between groups were assessed using analysis of variance or t-test with Prism 5.0 software (GraphPad Software, Inc., San Diego, CA). P < 0.05 was considered statistically significant.
Results
Identification of peptides targeting FGFR2IIIc with high affinity
A Ph.D.-7 library was used for biopanning phages targeting the extracellular domain of recombinant FGFR2IIIc protein (Fig. 1A) . After 3 rounds of screening, the phage titer was enriched by approximately 93-fold compared with that of the first round (Fig. 1B) . Simultaneously, during the screening process, the P/N value was also increased by round, and it reached 342 by the third round (Fig. 1C) . Table 1 also demonstrates that the FGFR2IIIc-targeting phages were effectively enriched after 3 rounds of screening. This result suggested that the screening was sufficiently specific. Then, 35 phage clones were randomly selected from the third round, and the peptide-coding DNA inserts of the phage clones were sequenced. 
After sequence alignment, we obtained 4 small peptides, which were named H1, H2, H3 and H4. The 4 peptides were synthesized, and their molecular weights were measured by mass spectrometry ( Supplementary Fig. S1A-D) . The relative binding affinity of the selected phage clones was determined qualitatively by ELISA. Among them, the clone displaying the sequence SNFLHLG, namely, H1, appeared to have the strongest binding ability (Fig. 1D) . Subsequently, a cell proliferation assay was performed to assess the biological function of these peptides using a CCK8 kit. The results indicated that the H1 peptide had the most remarkable effect of 4 peptides on cell growth (Fig. 1E) . Therefore, the H1 peptide was selected for further investigation.
The Fig. S2A-E) .
H1 peptide promotes the proliferation and motility of fibroblasts and vascular endothelial cells
Fibroblasts and HUVECs play such key roles in the proliferation phase of wound healing that their proliferation may effectively accelerate skin remodeling. In the cell proliferation assay, a CCK8 kit was used to evaluate the effect of the H1 peptide on fibroblasts BALB/c3T3 cells and HUVECs. In addition, bFGF (30 ng/mL) was used as a positive control ( Fig. 2A-C) . The results suggested that the H1 peptide (20 μM) markedly promoted the proliferation of BALB/c3T3 cells and HUVECs in a dose-dependent manner and enhanced the growth of BALB/c3T3 cells and HUVECs by 2-and 1.5-fold compared with the blank group, respectively.
In the process of skin wound healing, cell motility is an essential event in addition to cell proliferation. Therefore, we also examined the migration of fibroblasts and the angiogenesis of vascular endothelial cells following treatment with the H1 peptide. A cell scratch assay was conducted, and the results confirmed that, similar to the function of, the H1 peptide enhanced the migration of BALB/c3T3 cells significantly, and its effect was approximately 6-fold that of the blank group (Fig. 2D, E) . The results of the endothelial cell tube formation assay revealed that the H1 peptide clearly promoted tube formation by HUVECs (Fig. 2F, G) . In addition, the effect of the H1 peptide on angiogenesis in vivo was evaluated using a chick embryo chorioallantoic membrane assay (Fig. 2H, I ). We observed clearly that both the H1 peptide and bFGF (100 ng/mL) up-regulated angiogenesis in the chorioallantoic membrane. In addition, the H1 peptide functioned over over a concentration gradient in which the most significant effect was at a concentration of 1000 μM.
H1 peptide improves the impairing effect on wound healing in a rat full-thickness wound model in vivo
In addition to the in vitro determinations, we evaluated the effect of the H1 peptide on accelerating skin wound healing in vivo. We established a rat full-thickness wound model. In this experiment, bFGF (100μg/mL) was used as a positive control. Compared with the P<0.05 was considered to be statistically significant.
(B) GO (biological p r o c e s s e s ) enrichment analysis using topGO (version 2.18.0). The ordinates represent the enriched GO term; the abscissa denotes gene ratio (the number of genes associated with this biological process / the total number of genes); the size of the dots indicates the number of genes enriched in this biological process, and the color of the dots corresponds to the range of negative log10Pvalues. Colors from green to red indicate that negative log10Pvalue are from low to high or that the degree of enrichment is from low to high. (C) KEGG pathway enrichment analysis using KOBAS (version 3.0). The ordinates represent the enriched KEGG pathway. The above data analyses with P<0.05 were considered statistically significant. (D) qPCR analysis validated 6 genes that were differentially expressed between the H1 peptide-treatment group and the control samples by RNA-Seq. TGFB1, PRKCG, JUND, HSPB1, DUSP15, and DUSP8 were evaluated, and 3 independent experiments were performed for qPCR validation. GAPDH was used as a housekeeping control. Fold change was calculated using the 2 −∆∆Ct method. (E) Effect of the H1 peptide on the AKT and ERK1/2 signaling pathways. In western blot analysis, phospho-AKT (p-Ser473), total AKT, phospho-ERK1/2 (Thr202/Tyr204), and total ERK were detected. HUVECs were treated with the H1 peptide at different times (15, 30, normal saline treatment group (blank control), we observed that the scabs in the bFGF and the H1 peptide group sloughed earlier and the new skin tissues were exposed preferentially (Fig.  3A) . The H1 peptide also showed no side effects on body weight, general health, or the behavior of the rats. Moreover, the results of HE staining confirmed that both the H1 peptide and bFGF led to a more favorable impairing effect on the dermis, epidermis, and hair follicles (Fig. 3B ). An immunohistochemistry assay was conducted to further the investigation. PCNA is a marker of cell proliferation, CK19 is a marker of re-epithelialization, and CD31 is a marker of vascular endothelial cells. An increased number of cells was stained for these 3 markers both the H1 peptide and bFGF groups compared with the untreated group (Fig. 3C, D) .
H1 peptide induces phosphorylation of the PI3K-AKT and MAPK-ERK1/2 pathways and the secretion of VEGF
What is the molecular mechanism underlying the effect of the H1 peptide in wound healing? To answer this question, we performed the RNA-Seq technique, a large-scale transcriptome sequencing technology, to examine HUVECs treated with the H1 peptide. In this study, DEGs (P < 0.05) were defined as genes that were significantly enriched or depleted in the treatment group compared with the control group. Our results indicated that a total of 487 genes were differentially expressed of which 235 were up-regulated, and 252 were down-regulated in the treatment group (Fig. 4A) . Table 2 lists some statistically significant DEGs.
On the basis of the RNA-Seq results, GO annotation (biological process) analysis indicated that the biological process of "response to wound" was remarkably enriched (Fig. 4B) . In addition, KEGG pathway analysis revealed that some pathways were significantly enriched, such as the MAPK, PI3K-AKT and VEGF signaling pathways (Fig. 4C) .
To ensure the credibility of the RNA-Seq results, 6 up-regulated genes were randomly selected to be confirmed by qPCR assay. The results were consistent, verifying that the RNASeq data were convincing (Fig. 4D) .
It is well documented that the PI3K-AKT and MAPK signaling pathways are critical in regulating cell proliferation [32] [33] [34] [35] . In this study, KEGG analysis provided similar results. A western blot assay also presented corresponding results that the phosphorylation levels of AKT and ERK were significantly increased in the treatment group (Fig. 4E) , definitively indicating that the H1 peptide activated the AKT and ERK signaling pathways.
Many cytokines, such as transforming growth factor (TGF)-β, interleukin (IL)-6, and VEGF, are important in wound healing [7, 8, 36] . VEGF, in particular, is a key regulator of physiological angiogenesis during skeletal growth, embryogenesis and reproductive functions [37, 38] , and wound healing [39] [40] [41] . According to KEGG analysis, the VEGF signaling pathway was (Fig. 4F ). In addition, immunohistochemistry indicated that the expression of VEGF was greatly increased in both the H1 peptide and bFGF groups (Fig. 4G,  H) . Collectively, these results suggested that the H1 peptide had a gain-of-function to improve skin wound healing by activating the PI3K-AKT and MAPK-ERK1/2 signaling pathways and simultaneously inducing the expression of VEGF.
Molecular docking analysis of H1 peptide binding with FGFR2IIIc
To explore further the structural biology mechanism of the H1 peptide, LeDock software 42 was used to simulate the binding model of the H1 peptide and extracellular segment of FGFR2IIIc. The crystal structure of the FGFR2IIIc extracellular domain was derived from the Protein Data Bank (PDB code: 1EV2). Docking scores were calculated by the binding free energies. In the process of docking, the entire F chain of FGFR2IIIc was used as our docking area. The F chain contains the D2 and D3 regions of the extracellular domain of FGFR2IIIc, which is the critical region for FGFR2IIIc binding to its ligand. The software was set to sort the first 20 conformations according to the scoring function. Docking results indicated that the 20 binding conformations were all concentrated in the D2-D3 linker region ( Supplementary Fig. S3 ). According to the above preliminary docking results, the D2-D3 linker region was selected as our further docking area in which LeDock was rerun for a conformational search. The optimal conformation was obtained as our analysis object.
The docking results indicated that the H1 peptide was located in the active pocket of FGFR2IIIc, which was comprised of Val249, Glu250, Arg251, Ser252, Lys279, Tyr281, Ser282, Asp283, Gln285, Pro286, and Asp321, and formed a wide range of noncovalent interactions 
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Cellular Physiology and Biochemistry with them (Fig. 5A, B) . The H1 peptide was folded at the center of the Leu4 residue. Asp283 in FGFR2IIIc was located in the geometric center of the H1 peptide binding pocket, forming hydrogen bonding interactions with His5, Leu4, and Phe3 of the H1 peptide. Among the H1 peptide sequence, the benzene ring of Phe3 and the imidazolyl group of His5 formed pi bonds with Val249 and Pro286 of FGFR2IIIc, respectively; the amide groups of Asn2 and an amino group of Leu6 formed a hydrogen bond with Asp283 of FGFR2IIIc, respectively; Leu4 and Ser1 were structurally located on both sides of the D2-D3 linker, both of which were folded toward the inside of the active pocket to maintain the stability of the binding of the H1 peptide to the active pouch. Recorded X-ray diffraction data have indicated that the sites of bFGF interactions with FGFR2IIIc are located in the D2-D3 linker region, in which Leu166, Ala168, Pro170, Val249, Arg251, Asp283, Val317, Asn318, and Asp321 are the core amino acids of these interactions 43. Compared with the binding mode of bFGF and FGFR2IIIc, the H1 peptide had strong similarity and exhibited perfect geometric matching in the active cavity of the FGFR2IIIc receptor. Subsequently, we conducted molecular dynamics simulations of 50 ns to verify the stability of the H1-FGFR2IIIc complex in ionic solvents. The root mean square deviation (RMSD) parameter is an important index to measure whether a system is stable [44, 45] . The results indicated that the RMSD value of the H1-FGFR2IIIc complex began to increase sharply at 14 ns, reached its peak at 17 ns, and then gradually stabilized (Fig. 5C ). At 14 ns, Ser1 and Leu4 continued to maintain the geometric match of the H1 peptide with the D2-D3 linker associated with the initial conformation. However, some changes also remained. In addition to the formation of the pi bond with Val249, the benzene ring of Phe3 increased the formation of the pi bond with Ala168, Val169 and Pro170 in the active pocket, and the D2-D3 linker region of FGFR2IIIc was folded inward at the center of the H1 peptide, leading to a deeper FGFR2IIIc activity pocket (Fig. 5D, E) . Simultaneously, the folding was basically restored after 23 ns, and the folding time was consistent with the time of RMSD change.
Collectively, these results suggested that the H1 peptide had a dynamic effect on FGFR2IIIc and that the residues of the H1 peptide interacting with FGFR2IIIc basically included the core residues of bFGF and FGFR2IIIc binding.
Discussion
In this study, using phage display, we identified a novel small peptide, H1, targeting FGFR2IIIc with high affinity. As the H1 peptide demonstrated potentially facilitative effects on skin wound healing, we also explored its mechanism in vitro, in vivo, and at the structural biology level. In brief, the results indicated that the H1 peptide promoted the proliferation and motility of fibroblasts and vascular endothelial cells (Fig. 2) . It also promoted angiogenesis in the chick chorioallantoic membrane and accelerated wound healing in a rat full-thickness wound model in vitro (Fig. 3) . The H1 peptide activated the PI3K-AKT and MAPK-ERK1/2 signaling pathways and simultaneously induced the secretion of VEGF (Fig.  4) . It also exhibited the highest affinity with FGFR2IIIc (K d ≈ 32.1 nM) compared with other FGFRs (Figs. 1F and S2) , and its binding model was further revealed using molecular docking calculations and molecular dynamics simulations (Fig. 5) .
Using a phage-displayed peptide library, 4 small peptides were obtained in this study, H1, H2, H3, and H4. Although all 4 peptides showed high affinities with FGFR2IIIc, only the H1 peptide had the desired bioactivity (Fig. 1E) . Referring to the structural biology results (Fig. 5) , we assumed that the H2, H3, and H4 peptides may have different binding sites with FGFR2IIIc that led to the distinct spatial structural changes in FGFR2IIIc. Moreover, the binding mode of the H1 peptide to FGFR2IIIc was highly similar to that of bFGF and FGFR2IIIc, indicating that the H1 peptide could cause FGFR2IIIc to undergo conformational changes similar to those that occur in the presence of bFGF (Fig. 5A, B) . In addition, it is welldocumented that bFGF activates the intracellular PI3K-AKT and MAPK signaling pathways [46, 47] . Similarly, the H1 peptide could induce the phosphorylation of the PI3K-AKT and Cellular Physiology and Biochemistry
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MAPK-ERK1/2 pathways in vitro (Fig. 4) . It suggested that the H1 peptide must execute the considerable biological function of bFGF. Our institute developed recombinant bFGF for the treatment of for burns, scalds, and chronic ulcers 20 years ago. However, because recombinant bFGF degrades easily, it requires strict storage and transport conditions. ln clinical applications, it also leads to the low accumulation of bFGF at on therapeutic sites, an undesired effect. Compared with recombinant proteins, small peptides have many advantages such as small molecular weight and low production cost. As the H1 peptide has such a strong effect on cell proliferation, we believe that it could be a potential candidate drug to replace bFGF for skin repair. Of course, the application of the H1 peptide should be strictly evaluated in cases of abnormal cell proliferation, such as scars, tumor, and fibrosis.
In this study, we used computational biology software to examine the binding patterns of the H1 peptide to FGFR2IIIc (Fig. 5A, B) . The difficulty is that the H1 peptide has great flexibility. To solve such a problem, simulated annealing and genetic algorithms were combined to optimize semi-flexible docking. Meanwhile, we monitored the process of forming the binding pattern by long-time molecular dynamics simulation (Fig. 5C ). In the course of molecular dynamics simulation, we used the interval sampling method to obtain non-covalent bond formation of the H1-FGFR2IIIc complex. This may improve the accuracy of molecular docking and further define the stability of the H1-FGFR2IIIc complex. The approach we employed may prompt other investigators to simulate peptide-protein complexes in the future.
Conclusion
This study demonstrated that the H1 peptide played a biological role by activating FGFR2IIIc. Compared with the natural ligand bFGF, no significant functional differences were observed in this study. However, because they are so different in sequence, the H1 peptide may have unknown functions or characteristics. In addition, the members of the receptor tyrosine kinase family have high homology [48] . Thus, the H1 peptide may bind to other receptor tyrosine kinase proteins and affect the relevant signaling pathways. To address these issues, the H1 peptide must be explored deeply in the future.
In brief, we discovered a novel small peptide for the treatment of skin wounds which may be developed as a prospective candidate drug.
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